Surrogate Efficacy Endpoints in Oncology Trials

By Markman Maurie  

Pharmaceutical Medicine, Vol. 23, Iss. 5-6, 2009-10 ,pp. : 283-287

Adis International

Access to resources Recommend Favorite

When is a Proof-of-Concept (POC) not a POC? Pomaglumetad (LY2140023) as a Case Study for Antipsychotic Efficacy

By  

Current Pharmaceutical Design, Vol. 21, Iss. 26, 2015-01 ,pp. : 3788-3796

Bentham Science Publishers

Access to resources Recommend Favorite

Safety and Proof-of-Concept Efficacy of Inhaled Drug Loaded Nano- and Immunonanoparticles in a c-Raf Transgenic Lung Cancer Model

By  

Current Cancer Drug Targets, Vol. 13, Iss. 1, 2013-01 ,pp. : 11-29

Bentham Science Publishers

Access to resources Recommend Favorite

Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study

By Eser Daniela   Schüle Cornelius   Baghai Thomas   Floesser Anette   Krebs-Brown Axel   Enunwa Michaela   Motte Stephan   Engel Rolf   Kucher Klaus   Rupprecht Rainer  

Psychopharmacology, Vol. 192, Iss. 4, 2007-07 ,pp. : 479-487

Springer Publishing Company

Access to resources Recommend Favorite

Anesthetic Cardioprotection in Clinical Practice From Proof-of-Concept to Clinical Applications

By  

Current Pharmaceutical Design, Vol. 20, Iss. 36, 2014-11 ,pp. : 5706-5726

Bentham Science Publishers

Access to resources Recommend Favorite